CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial

Cited by papers we hold 11

• Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors · 2024
  No notice
• Current and future immunotherapeutic approaches in pancreatic cancer treatment · 2024
  No notice
• CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments · 2022
  No notice
• Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects · 2021
  No notice
• CAR T cells in solid tumors: challenges and opportunities · 2021
  No notice
• Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies · 2020
  No notice
• Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma · 2020
  No notice
• Target selection for CAR-T therapy · 2019
  No notice
• CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy · 2019
  No notice
• The role of CD133 in cancer: a concise review · 2018
  No notice
• Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma · 2018
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.